CYCLOPHOSPHAMIDE MONOHYDRATE, FLUDARABINE PHOSPHATE clinical trials

An adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerability, and clinical activity in patients with relapsed/refractory acute myeloid leukaemia (RESOLVE AML 001)

This study is testing a new treatment (CCTx-001) for adults with acute myeloid leukaemia (AML) that has returned or not responded to previous treatments. It aims to find the right dose and check how safe and effective it is.